Ignite Creation Date:
2025-12-25 @ 4:10 AM
Ignite Modification Date:
2026-02-25 @ 4:52 AM
Study NCT ID:
NCT02950220
Status:
COMPLETED
Last Update Posted:
2019-07-30
First Post:
2016-10-28
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
Sponsor:
Kami Maddocks
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell … | View |
| None | Grade 1 Follicular Lymphoma | View |
| None | Grade 2 Follicular Lymphoma | View |
| None | Grade 3a Follicular Lymphoma | View |
| None | Mediastinal Lymphoma | View |
| None | Recurrent B-Cell Non-Hodgkin Lymphoma | View |
| None | Recurrent Burkitt Lymphoma | View |
| None | Recurrent Diffuse Large B-Cell Lymphoma | View |
| None | Recurrent Follicular Lymphoma | View |
| None | Recurrent Lymphoplasmacytic Lymphoma | View |
| None | Recurrent Mantle Cell Lymphoma | View |
| None | Recurrent Marginal Zone Lymphoma | View |
| None | Recurrent Waldenstrom Macroglobulinemia | View |
| None | Refractory B-Cell Non-Hodgkin Lymphoma | View |
| None | Refractory Burkitt Lymphoma | View |
| None | Refractory Diffuse Large B-Cell Lymphoma | View |
| None | Refractory Follicular Lymphoma | View |
| None | Refractory Lymphoplasmacytic Lymphoma | View |
| None | Refractory Mantle Cell Lymphoma | View |
Keywords: